The Italian quality control study for evaluation of CD4 cells in centres involved in the treatment of HIV‐1 patients

• Published in: Clinical and experimental immunology 1998-03, Vol.111 (3), p.564-573
• Main Authors: PANDOLFI, F, ALARIO, C, GIRARDI, E, RAVA, L, IPPOLITO, G, KUNKL, A, AIUTI, F
• Format: Article
• Language: English
• Subjects: Biological and medical sciences; CD4; HIV‐1; Human viral diseases; Infectious diseases; Medical sciences; Original; quality control; Viral diseases; Viral diseases of the lymphoid tissue and the blood. Aids
• ISSN: 0009-9104; 1365-2249
• DOI: 10.1046/j.1365-2249.1998.00520.x

We report on the experience of establishing a national network for a quality control programme in evaluating CD4 cell counts in most Italian centres involved in the care of patients with HIV disease. The 68 centres were divided according to their geographical location into eight groups, and twice a year (tests A and B) they received three coded whole blood samples (two were replicates of the same sample) obtained from two informed HIV+ patients, one with CD4 counts/mm3 expected to be  300. The medians of the determinations performed by the labs involved in each of the eight areas were taken as the ‘true’ values for each sample. Unsatisfactory performances for percentage of CD4 cells were identified as a CD4 analysis with residual values ≥ ± 5% and with deviates ≥ ± 2. For absolute numbers of CD4 cells, an unsatisfactory performance was defined as CD4 counts with residual > ± 100 CD4 cells/mm3 and with deviates ≥ ± 2. The residual value is the CD4 value reported by each lab minus the median value. The deviate is the residual divided by the modified interquartile range (IQR × 0.75). Most of the centres provided reliable results. However, some labs failed to provide satisfactory results for percentages (6.25% of the tested labs for test A and 6.17% for test B) or absolute numbers (16.25% test A and 12.34% test B). Only 3.7% of the labs gave unsatisfactory results in both tests. Four of the unsatisfactory results from the two tests gave an error in absolute numbers > ± 200 CD4 cells/mm3. Our data suggest that most Italian labs provide reliable results in evaluating the numbers of CD4 cells in HIV‐1+ samples, but the importance of running a quality control programme is highlighted by our experience with those centres which provide unsatisfactory data which may lead to incorrect classification of the patients or assessment of treatment.